US Food and Drug Administration Deputy Commissioner
Woodcock confirmed the news in an email.
Woodcock, who joined the FDA in 1986, received accolades from colleagues upon news of her retirement. Several crucial FDA decisions during her tenure brought her into the limelight and attracted criticism from lawmakers and advocacy groups.
Numerous targeted cancer drugs were approved under her watch. These transformed care of the disease from a death sentence to a chronic ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.